Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. has strengthened its financial and operational foundation through a $5 million tranche from a $25 million financing agreement, enabling the advancement of its diverse clinical programs. The successful completion of the first-in-human trial for diabetic foot ulcers has showcased promising efficacy and safety, positioning the company favorably within the regenerative medicine sector. Additionally, the partnership with Charles River for cGMP manufacturing enhances FibroBiologics' capacity to scale production efficiently and comply with regulatory standards, reinforcing its leadership position and potential market reach in multiple therapeutic areas.

Bears say

FibroBiologics Inc. faces significant challenges as a clinical-stage company with a lack of proven product viability and an extensive reliance on unproven fibroblast-based therapies targeted at chronic diseases, which introduces substantial operational risks. Additionally, the company's development pipeline appears heavily focused on therapeutic areas, such as diabetic foot ulcers, that, while presenting an unmet need, may encounter intense competition and regulatory hurdles, potentially delaying market entry and commercialization. Financial stability is further jeopardized by the inherent uncertainties of clinical trials and the requirement for substantial capital investment without currently generating revenue, which could limit the company’s ability to sustain its operations and fulfill strategic objectives.

Fibrobiologics Inc (FBLG) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.